
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 05, 2024

RxSight, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

001-40690
(Commission File Number)

94-3268801
(IRS Employer
Identification No.)

100 Columbia
Aliso Viejo, California
(Address of Principal Executive Offices)

92656
(Zip Code)

Registrant's Telephone Number, Including Area Code: (949) 521-7830

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|----------------------|---|
| Common Stock, par value \$0.001 per share | RXST | The Nasdaq Stock Market LLC |

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2024, RxSight, Inc. (the “Company”) issued a press release announcing its results of operations and financial condition for the three and six months ended June 30, 2024. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

The information furnished in this Current Report on Form 8-K under Item 2.02 and the exhibit attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

The following exhibit is furnished as part of this report:

| Exhibit number | Description |
|-----------------------|--|
| 99.1 | Press Release dated August 5, 2024. |
| 104 | Cover Page Interactive Data File (embedded within the inline XBRL document). |

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

RxSight, Inc.

Date: August 5, 2024

By: /s/ Shelley Thunen

Name: Shelley Thunen

Title: Co-President and Chief Financial Officer

RXSIGHT, INC. REPORTS SECOND QUARTER 2024 FINANCIAL RESULTS

Aliso Viejo, Calif. (NASDAQ: RXST) – August 5, 2024 – RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today reported financial results for the three months ended June 30, 2024.

Key Quarterly Highlights

- Reported second quarter 2024 revenue of \$34.9 million, an increase of 68% compared to the second quarter of 2023, reflecting:
 - The sale of 24,214 Light Adjustable Lenses (LAL™/LAL+™), representing a 92% increase in procedure volume compared to the second quarter of 2023;
 - The sale of 78 Light Delivery Devices (LDD™s), representing a 16% increase in unit sales compared to the second quarter of 2023 and expanding the installed base to 810 LDDs at the end of the quarter, representing a 55% increase compared to the end of the second quarter of 2023; and
- The company increased its 2024 full-year revenue, and operating expense guidance.

“In the second quarter, we continued to make significant progress in the adoption of adjustability as a new standard in the premium market, highlighted by robust LDD sales and the positive reception of the recently launched LAL+,” said Dr. Ron Kurtz, Chief Executive Officer and President of RxSight. “The ability to adjust the optical power of the lens after surgery is increasingly valued by both doctors and patients for the excellent clinical outcomes and personalized approach it enables. As we move forward, we remain dedicated to expanding our presence and driving innovation within the global premium IOL market.”

Second Quarter Financial Results

In the second quarter of 2024, total revenue was \$34.9 million, an increase of 68% compared to \$20.8 million in the second quarter of 2023. Revenue growth was driven by a 92% increase in LAL revenue and a 32% increase in LDD revenue, compared to the second quarter of 2023.

Gross profit for the second quarter of 2024 was \$24.3 million or 69.5% of revenue, an increase of \$12.2 million or 102% compared to gross profit of \$12.0 million or 57.8% of revenue for the second quarter of 2023. The favorable shift in product mix toward LAL sales drove the increase in gross profit in the quarter, along with reduced costs to produce LALs, primarily due to higher production volumes and increased margin on the LDD due to lower material costs and an increase in the average selling price.

Total operating expenses for the second quarter of 2024 were \$32.6 million, a 27% increase from \$25.6 million in the second quarter of 2023, reflecting the company’s ongoing investments to grow its LDD installed base and support increased LAL sales volume.

In the second quarter of 2024, the company reported a net loss of \$(6.1) million, or \$(0.16) per basic and diluted share, compared to a net loss of \$(13.8) million, or \$(0.40) per basic and diluted share in the second quarter of 2023. Adjusted net earnings in the second quarter of 2024 were \$0.0 million, or \$0.00

per basic and diluted share, compared to an adjusted net loss of \$(9.5) million, or \$(0.28) per basic and diluted share in the second quarter of 2023.

Cash, cash equivalents and short-term investments as of June 30, 2024, were \$233.3 million compared to \$125.4 million on March 31, 2024. The second quarter 2024 cash balance includes \$107.5 million in net proceeds from the company's confidentially marketed public offering, which closed on May 13, 2024.

2024 Guidance

The company increased its 2024 full-year revenue and operating expense guidance as follows:

- Revenue in the range of \$139.0 million to \$140.0 million, representing implied growth of 56% to 57% compared to 2023, up from prior guidance of \$132.0 million to \$137.0 million;
- Operating expenses in the range of \$135.0 million to \$136.0 million, representing an implied increase of 30% to 31% compared to 2023, up from prior guidance of \$126.0 million to \$130.0 million and including higher non-cash stock-based compensation expense guidance in the range of \$29.0 million to \$30.0 million, up from prior guidance of \$22.0 million to \$25 million.

Additionally, gross margin full-year 2024 guidance remained unchanged in the range of 68% to 70%.

Conference Call

On Monday, August 5, 2024, at 1:30 p.m. Pacific Time, the company will host a conference call to discuss its second quarter 2024 financial results. Participants may register for the call and listen through a live and archived webcast of the event available for one year at <https://investors.rxsight.com/>.

About RxSight, Inc.

RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjustable Lens® (LAL™/LAL+™, collectively the "LAL"), RxSight Light Delivery Device (LDD™) and accessories, is the first and only commercially available intraocular lens (IOL) technology that can be adjusted after surgery, enabling doctors to customize and deliver high-quality vision to patients after cataract surgery. Additional information about RxSight can be found at www.rxsight.com.

Forward-Looking Statements

This press release contains forward-looking statements, including management's views regarding RxSight's significant progress in the adoption of adjustability as a new standard in the premium IOL market, the positive reception of the recently launched LAL+, the increasing value recognized by doctors and patients for excellent clinical outcomes and personalized approach, expanding the company's presence, driving innovation within the global premium IOL market, and RxSight's projected revenue, gross margin, and operating expenses for 2024. Such statements relate to future events or our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed, implied or inferred by these forward-looking statements, and among other things, our ability to maintain cash balances and successfully commercialize or partner our product candidates currently under development. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "would," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "projects," "potential," or "continue" or the negative of such terms and other



same terminology. These statements are only predictions based on our current expectations and projections about future events. You should not place undue reliance on these statements. Actual events or results may differ materially. In evaluating these statements, you should specifically consider various factors, including the risk factors that may be found in the section entitled Part II, Item 1A (Risk Factors) in the Quarterly Report on Form 10-Q for the three months ended June 30, 2024, filed with the Securities and Exchange Commission (SEC) on or about the date hereof, and the other documents that RxSight may file from time to time with the SEC. These and other factors may cause our actual results to differ materially from any forward-looking statement. We undertake no obligation to update any of the forward-looking statements after the date of this press release to conform those statements to reflect the occurrence of unanticipated events, except as required by applicable law.

Company Contact:

Shelley B. Thunen
Chief Financial Officer
sthunen@rxsight.com

Investor Relations Contact:

Oliver Moravcevic
VP, Investor Relations
omoravcevic@rxsight.com

RxSIGHT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
AND COMPREHENSIVE LOSS (UNAUDITED)
(In thousands, except share and per share amounts)

| | Three Months Ended June 30, | | Six Months Ended June 30, | |
|---|-----------------------------|-------------|---------------------------|-------------|
| | 2024 | 2023 | 2024 | 2023 |
| Sales | \$ 34,887 | \$ 20,810 | \$ 64,399 | \$ 38,299 |
| Cost of sales | 10,637 | 8,795 | 19,464 | 15,919 |
| Gross profit | 24,250 | 12,015 | 44,935 | 22,380 |
| Operating expenses: | | | | |
| Selling, general and administrative | 24,292 | 18,239 | 47,616 | 34,492 |
| Research and development | 8,291 | 7,401 | 16,322 | 14,608 |
| Total operating expenses | 32,583 | 25,640 | 63,938 | 49,100 |
| Loss from operations | (8,333) | (13,625) | (19,003) | (26,720) |
| Other income (expense), net: | | | | |
| Interest expense | (6) | (1,568) | (11) | (3,075) |
| Interest and other income | 2,276 | 1,777 | 3,860 | 3,168 |
| Loss on extinguishment of term loan | — | (362) | — | (362) |
| Loss before income taxes | (6,063) | (13,778) | (15,154) | (26,989) |
| Income tax expense | 16 | 26 | 25 | 27 |
| Net loss | \$ (6,079) | \$ (13,804) | \$ (15,179) | \$ (27,016) |
| Other comprehensive (loss) income | | | | |
| Unrealized (loss) gain on short-term investments | (64) | (65) | (109) | 19 |
| Foreign currency translation (loss) gain | (1) | 1 | (4) | 3 |
| Total other comprehensive (loss) income | (65) | (64) | (113) | 22 |
| Comprehensive loss | \$ (6,144) | \$ (13,868) | \$ (15,292) | \$ (26,994) |
| Net loss per share: | | | | |
| Basic & diluted | \$ (0.16) | \$ (0.40) | \$ (0.40) | \$ (0.82) |
| Weighted-average shares used in computing net loss per share: | | | | |
| Attributable to common stock, basic & diluted | 38,455,955 | 34,498,265 | 37,649,521 | 33,075,585 |

RxSIGHT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED)
(In thousands, except share and per share amounts)

| | June 30, 2024 | December 31, 2023 |
|---|-------------------|----------------------|
| | (Unaudited) | |
| Assets | | |
| Current assets: | | |
| Cash and cash equivalents | \$ 24,445 | \$ 9,692 |
| Short-term investments | 208,839 | 117,490 |
| Accounts receivable | 25,723 | 20,281 |
| Inventories | 19,443 | 17,421 |
| Prepaid and other current assets | 2,773 | 3,523 |
| Total current assets | 281,223 | 168,407 |
| Property and equipment, net | 12,444 | 10,841 |
| Operating leases right-of-use assets | 10,818 | 2,444 |
| Restricted cash | 711 | 711 |
| Other assets | 303 | 147 |
| Total assets | \$ 305,499 | \$ 182,550 |
| Liabilities and stockholders' equity | | |
| Current liabilities: | | |
| Accounts payable | \$ 5,095 | \$ 3,863 |
| Accrued expenses and other current liabilities | 13,787 | 15,239 |
| Lease liabilities | 736 | 1,801 |
| Total current liabilities | 19,618 | 20,903 |
| Long-term lease liabilities | 10,674 | 1,211 |
| Other long-term liabilities | — | 74 |
| Total liabilities | 30,292 | 22,188 |
| Commitments and contingencies | | |
| Stockholders' equity: | | |
| Common stock, \$0.001 par value, 900,000,000 shares authorized, 39,617,334 shares issued and outstanding as of June 30, 2024 and 36,139,513 shares issued and outstanding as of December 31, 2023 | 40 | 36 |
| Preferred stock, \$0.001 par value, 100,000,000 shares authorized, no shares issued and outstanding | — | — |
| Additional paid-in capital | 885,104 | 754,971 |
| Accumulated other comprehensive loss | (118) | (5) |
| Accumulated deficit | (609,819) | (594,640) |
| Total stockholders' equity | 275,207 | 160,362 |
| Total liabilities and stockholders' equity | \$ 305,499 | \$ 182,550 |

Non-GAAP Financial Measures

To supplement our unaudited condensed consolidated financial statements presented under generally accepted accounting principles in the United States (“GAAP”), we believe certain non-GAAP measures, including adjusted net earnings (loss), and adjusted net earnings (loss) per share, basic and diluted, provide useful information to investors and are useful in evaluating our operating performance. For example, we exclude stock-based compensation expense and loss on extinguishment of debt because these expenses are non-cash in nature and we believe excluding these items provides meaningful supplemental information regarding our operational performance and allows investors the ability to make more meaningful comparisons between our operating results and those of other companies.

We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. In addition, other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance. A reconciliation is provided below for each non-GAAP financial measure to the most directly comparable financial measure stated in accordance with GAAP. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures, and not to rely on any single financial measure to evaluate our business.

Adjusted Net Earnings (Loss) and Adjusted Net Earnings (Loss) Per Share

Adjusted net earnings (loss) is a non-GAAP financial measure that we define as net earnings (loss) adjusted for (i) stock-based compensation and (ii) loss on extinguishment of term loan. We believe adjusted net earnings (loss) provides investors with useful information on period-to-period performance as evaluated by management and comparison with our past financial performance and is useful in evaluating our operating performance compared to that of other companies in our industry, as this metric generally eliminates the effects of certain items that may vary from company to company for reasons unrelated to overall operating performance.

Reconciliations of net earnings (loss) to adjusted net earnings (loss) and the presentation of adjusted net earnings (loss) per share, basic and diluted, are as follows:

RxSIGHT, INC.
GAAP To NON-GAAP RECONCILIATIONS (UNAUDITED)
(In thousands, except share and per share amounts)

| | Three months ended June 30, | | For the six months ended June 30, | |
|---|-----------------------------|-------------|-----------------------------------|-------------|
| | 2024 | 2023 | 2024 | 2023 |
| Common Stock | | | | |
| Numerator: | | | | |
| Net loss available to stockholders, basic and diluted | \$ (6,079) | \$ (13,804) | \$ (15,179) | \$ (27,016) |
| Add: | | | | |
| Stock-based compensation | 6,105 | 3,955 | 10,801 | 7,250 |
| Loss on extinguishment of term loan | — | 362 | — | 362 |
| Adjusted net income (loss) available to common stockholders, basic and diluted: | \$ 26 | \$ (9,487) | \$ (4,378) | \$ (19,404) |
| Denominator: | | | | |
| Weighted-average shares outstanding, basic | 38,455,955 | 34,498,265 | 37,649,521 | 33,075,585 |
| Weighted-average shares outstanding, diluted | 44,799,864 | 34,498,265 | 37,649,521 | 33,075,585 |
| Adjusted net earnings (loss) per share, basic | \$ 0.00 | \$ (0.28) | \$ (0.12) | \$ (0.59) |
| Adjusted net earnings (loss) per share, diluted | \$ 0.00 | \$ (0.28) | \$ (0.12) | \$ (0.59) |

